Pharmaceutical Technology



News Analysis Sectors Themes Insights Companies Events ⊗Buy Reports Newsletters


South Korea and Australia on the rise as clinical research hubs

Novotech's vice president highlighted the APAC region's growing clinical presence, drawing attention to Australia and South Korea. Akosua Mireku | June 12, 2024





r. Yooni Kim, the vice president of clinical services at Novotech, says Australia and South Korea are emerging as bubbling clinical research hubs in the Asia-Pacific (APAC) region.



At the ongoing <u>Outsourcing in Clinical Trials UK and Ireland conference</u>, Kim led a session on "Unlocking APAC potential to enhance your clinical program." The event, held 11 - 12 June, gathered clinical trial professionals to debate issues within the sector. At Kim's talk, she highlighted the 142 European biotech companies that have conducted single-country or multinational clinical trials in the APAC region between 2019 and 2023, saying that the region has become the "fastest-growing global market for pharmaceutical sales".

In particular, Kim highlighted South Korea's "attractive" government frameworks for clinical research. For example, the Korea Health Industry Development Institute (KHIDI) has created a national artificial intelligence (AI) platform that integrates data from several healthcare institutes to support clinical trials, match patients with studies, and monitor trial progress. Moreover, Samsung Medical Center is also growing partnerships with AI startups for data analysis and patient outreach, she adds.

Partner Content



The future of eClinical technology interoperability: Have your

A new survey from GlobalData aims to gain insights into deploying new

By Viedoc Technologies

Go deeper with GlobalData

Impact of South Korea on the Pharmaceutical Industry - Thematic



Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic

© Data Insights
The gold standard of business intelligence.

Find out more >



"Australia also has a very streamlined process," says Kim, calling attention to the region's six – eight-week trial start-up timeline for private sites. This includes the period needed for an $\,$ application to go from an Ethics committee submission to approval. Furthermore, the country does not require a clinical trial application (CTA) or an investigational new drug (IND) application to conduct a study. Several biotech companies begin clinical trials in Australia as they simultaneously prepare US IND submissions, and choose to run their earlier phase studies in Australia before transitioning to the US for the later stages, said Kim. This makes the country particularly attractive as the US agencies accept clinical data from Australia for subsequent regulatory submissions, she adds.

Partner Content



The future of eClinical technology interoperability: Have your say

A new survey from GlobalData aims to gain insights into deploying new

By Viedoc Technologies

In 2024, the Australian government initiated its Clinical Trials Activity Initiative that aimed to provide $5750\mathrm{m}$ over 10 years between 2024/2025 and 2033/2034. The government plans to aid clinical trials addressing rare cancers, rare diseases, unmet needs, and bring investigator-led international clinical studies to Australia, as per the government website. The country has been taking actions to improve its global appeal as a clinical research superpower for several years, introducing a research and development (R&D) refund scheme with up to 43.5% cash refunds that was launched in July 2021.



Free Whitepaper Navigating the FDA Approval Processes:

Capitalize on Regulatory Expertise to Simplify the Complex

Over the last 10 years, the total cost to develop a pharmaceutical asset has more than doubled. This whitepaper outlines the global approval landscape, including pathways to approval and typical

mpediments to success. Download now for guidance on formulating
ead more V
y Novotech
Enter your work email
First name *
Last name *
Company name *
Job title *
Country Code *
Phone number *
Country*
I'm not a robot
y downloading this Whitepaper, you acknowledge that GlobalData may share our information with <u>Nexotech</u> and that your personal data will be used as escribed in their <u>Privacy Policy</u>
Submit

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your Visit our Privacy Policy for more information about our services, how Global Data





Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.

Sign up

Share <

Pharmaceutical Technology

The leading site for news and procurement in the pharmaceutical industry





About us Advertise with us License our content Editorial approach Newsletters

Privacy policy Terms and conditions Sitemap

Powered by V≡RDICT